{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:48:43Z","timestamp":1780418923838,"version":"3.54.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jpba.2023.115714","type":"journal-article","created":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T17:59:09Z","timestamp":1694282349000},"page":"115714","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["LC-PDA-QTof-MS characterization of the stress degradation products of Zanubrutinib: A novel BTK inhibitor"],"prefix":"10.1016","volume":"236","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9886-2180","authenticated-orcid":false,"given":"Murali Mohan","family":"Bhandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasish","family":"Swain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Ragampeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8417-0159","authenticated-orcid":false,"given":"Mohana Krishna Reddy","family":"Mudiam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2023.115714_bib1","first-page":"115","article-title":"Mantle-cell lymphoma","volume":"36","author":"Campo","year":"1999","journal-title":"Semin Hematol."},{"key":"10.1016\/j.jpba.2023.115714_bib2","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1172\/JCI61272","article-title":"Molecular pathogenesis of mantle cell lymphoma","volume":"122","author":"Jares","year":"2012","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.jpba.2023.115714_bib3","unstructured":"American Society of Hematology, (n.d.). \u3008https:\/\/ashpublications.org\/bloodadvances\/article\/5\/12\/2577\/476187\/Zanubrutinib-for-the-treatment-of-relapsed-or\u3009 (accessed May 26, 2023)."},{"key":"10.1016\/j.jpba.2023.115714_bib4","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood-2018-99-117956","article-title":"Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma from a Phase 2 Trial","volume":"132","author":"Song","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jpba.2023.115714_bib5","unstructured":"SpringerLink, (n.d.). \u3008https:\/\/link.springer.com\/article\/10.1007\/s40265\u2013019-01252\u20134\u3009 (accessed May 26, 2023)."},{"key":"10.1016\/j.jpba.2023.115714_bib6","unstructured":"PubMed, (n.d.). \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/12475179\/\u3009 (accessed May 26, 2023)."},{"key":"10.1016\/j.jpba.2023.115714_bib7","unstructured":"ScienceDirect, (n.d.). \u3008https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0165993613001313\u3009 (accessed May 26, 2023)."},{"key":"10.1016\/j.jpba.2023.115714_bib8","unstructured":"VDT, (n.d.). \u3008https:\/\/www.dovepress.com\/forced-degradation-studies-an-essential-tool-for-the-formulation-devel-peer-reviewed-fulltext-article-VDT\u3009 (accessed May 26, 2023)."},{"key":"10.1016\/j.jpba.2023.115714_bib9","unstructured":"RSC Advances (RSC Publishing), (n.d.). \u3008https:\/\/pubs.rsc.org\/en\/content\/articlelanding\/2016\/ra\/c5ra27965h\u3009 (accessed May 26, 2023)."},{"key":"10.1016\/j.jpba.2023.115714_bib10","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jpba.2015.12.045","article-title":"Characterization of forced degradation products and in silico toxicity prediction of Sofosbuvir: A novel HCV NS5B polymerase inhibitor","volume":"120","author":"Swain","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2023.115714_bib11","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/chromsci\/bmab137","article-title":"Forced degradation study of zanubrutinib: an LC\u2013PDA and LC\u2013MS approach","volume":"60","author":"Gollu","year":"2022","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.jpba.2023.115714_bib12","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.22214\/ijraset.2019.12163","article-title":"An Overview - International Conference on Harmonisation and ICH (Q1) Stability Testing Guideline for Pharmaceutical Development","volume":"7","author":"Pawar","year":"2019","journal-title":"Int. J. Res. Appl. Sci. Eng. Technol."},{"key":"10.1016\/j.jpba.2023.115714_bib13","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jasms.2008.12.012","article-title":"Neutral Loss of Isocyanic Acid in Peptide CID Spectra: A Novel Diagnostic Marker for Mass Spectrometric Identification of Protein Citrullination","volume":"20","author":"Hao","year":"2009","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"10.1016\/j.jpba.2023.115714_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113768","article-title":"LC and LC\u2013MS\/MS studies for identification and characterization of new degradation products of ibrutinib and elucidation of their degradation pathway","volume":"194","author":"Mehta","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2023.115714_bib15","unstructured":"Natural Product Reports (RSC Publishing), (n.d.). \u3008https:\/\/pubs.rsc.org\/en\/content\/articlelanding\/2016\/np\/c5np00073d\u3009 (accessed May 26, 2023)."},{"key":"10.1016\/j.jpba.2023.115714_bib16","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/j.jasms.2007.09.002","article-title":"Study of Michael-Michael-retro Michael Addition Catalyzed by 9-Amino-9-Deoxyepiquinine Using ESI-MS","volume":"18","author":"Wu","year":"2007","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"10.1016\/j.jpba.2023.115714_bib17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jpba.2017.05.012","article-title":"Identification of related substances in tofacitinib citrate by LC-MS techniques for synthetic process optimization","volume":"143","author":"Wu","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2023.115714_bib18","unstructured":"Bentham Science, (n.d.). \u3008https:\/\/benthamscience.com\/article\/33993\u3009 (accessed May 26, 2023)."},{"key":"10.1016\/j.jpba.2023.115714_bib19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jct.2004.08.006","article-title":"Experimental thermochemical study of three monosubstituted pyrazines","volume":"37","author":"Ribeiro da Silva","year":"2005","journal-title":"J. Chem. Thermodyn."},{"key":"10.1016\/j.jpba.2023.115714_bib20","unstructured":"The Journal of Organic Chemistry, (n.d.). \u3008https:\/\/pubs.acs.org\/doi\/10.1021\/jo051540n\u3009 (accessed May 26, 2023)."},{"key":"10.1016\/j.jpba.2023.115714_bib21","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/poc.1304","article-title":"Acid catalyzed 1, 2 Michael addition reaction: a viable synthetic route in designing fullerene core starlike macromolecule","volume":"21","author":"Singh","year":"2008","journal-title":"J. Phys. Org. Chem."},{"key":"10.1016\/j.jpba.2023.115714_bib22","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10973-008-9211-z","article-title":"Thermal behaviour of fentanyl and its analogues during flash pyrolysis","volume":"96","author":"Manral","year":"2009","journal-title":"J. Therm. Anal. Calor."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523004831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523004831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:32:59Z","timestamp":1760002379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708523004831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":22,"alternative-id":["S0731708523004831"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115714","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LC-PDA-QTof-MS characterization of the stress degradation products of Zanubrutinib: A novel BTK inhibitor","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115714","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115714"}}